MetaCap

Aurinia Pharmaceuticals (AUPH) vs Vera Therapeutics (VERA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aurinia Pharmaceuticals (AUPH) has outperformed Vera Therapeutics (VERA) over the past year, losing 6.3% versus a loss of 10.6%. Over five years, VERA leads with a -15.2% price change compared with -24.0% for AUPH. Aurinia Pharmaceuticals is the larger company by market cap ($1.97 billion vs $1.84 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AUPH-6.25%VERA-10.58%
+101%+42%-16%
Nov 21, 20251 yearNov 20, 2026
AUPH-48.37%VERA-18.43%
+80%-7%-93%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AUPH versus VERA key metrics
MetricAUPHVERA
Share price$14.70$25.45
Market cap$1.97B$1.84B
1-day change-1.28%-4.86%
YTD return-7.84%-49.74%
1-year return-6.25%-10.58%
5-year return-23.95%-15.17%
P/E ratio (TTM)6.45—
Forward P/E12.67—
EPS (TTM)$2.28$-5.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$283.06M—
Revenue growth (YoY)+20.38%—
Net income (latest FY)$287.20M$-299.62M
Gross margin88.46%—
Operating margin37.06%—
Net margin101.47%—
52-week high$19.25$56.05
52-week low$13.52$25.08
Distance from 52-week high-23.64%-54.59%
Analyst consensusbuystrong_buy
Avg. price target upside+25.85%+180.39%
Average volume858.74K1.95M
Shares outstanding134.00M72.30M
Employees128362
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aurinia Pharmaceuticals

AUPH stock →

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About Vera Therapeutics

VERA stock →

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 362 employees

AUPH vs VERA FAQ

Which is bigger, Aurinia Pharmaceuticals or Vera Therapeutics?

Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $1.97B compared with $1.84B for Vera Therapeutics (VERA).

Which stock has performed better over the past year, AUPH or VERA?

AUPH returned -6.25% over the past 12 months, compared with -10.58% for VERA (price return, excluding dividends). Past performance does not predict future results.

Are Aurinia Pharmaceuticals and Vera Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons